{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:42:20Z","timestamp":1788597740071,"version":"build-2803163510"},"reference-count":95,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"processing charges for the present manuscript"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2022,12,2]]},"DOI":"10.1080\/14787210.2022.2142118","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T23:14:30Z","timestamp":1668208470000},"page":"1603-1614","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-4251","authenticated-orcid":false,"given":"Takahisa","family":"Ohashi","sequence":"first","affiliation":[{"name":"Medical Affairs Department, Pfizer Japan Inc, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Kawai","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tateda","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease, Toho University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-018-0451-1"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"cit0004","unstructured":"Review on Antimicrobial Resistance [Internet]. Antimicrobial resistance: tackling a crisis for the health and wealth of nations; 2014 December [cited 2022 Aug 29]; [20 p.]. Available from: https:\/\/amr-review.org\/sites\/default\/files\/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf"},{"key":"cit0005","unstructured":"World Health Organization. [Internet]. Antimicrobial resistance and the United Nations sustainable development cooperation framework: guidance for United Nations country teams. [cited 2022 Aug 29]; [about 2 screens]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240036024"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.9b00076"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky019"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-018-0135-0"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24050892"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00681"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24173152"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab612"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.684515"},{"key":"cit0014","unstructured":"Federal Ministry of Health. Breaking through the wall: a call for concerted action on antibiotics research and development; Berlin: Federal Ministry of Health; 2017. [cited 2022 Aug 29]; [84 p.]. Available from: https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/5_Publikationen\/Gesundheit\/Berichte\/GUARD_Follow_Up_Report_Full_Report_final.pdf"},{"issue":"3","key":"cit0015","first-page":"209","volume":"8","author":"Littmann J","year":"2015","journal-title":"Public Health Ethics"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2201"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1139\/cjm-2013-0089"},{"key":"cit0018","first-page":"55","volume":"12","author":"Yagisawa M","year":"2019","journal-title":"Journal of Healthcare-associated Infection"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv339"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00101"},{"key":"cit0021","unstructured":"US Food and Drug Administration [Internet]. Guidance document: antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases; 2017 August [cited 2022 Aug 29]; [about 2 screens]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases"},{"key":"cit0022","unstructured":"European Medicines Agency [Internet]. European Medicines Agency. 1995-2022 Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections; 2013 October [cited 2022 Aug 29]; [20 p.]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections_en.pdf"},{"key":"cit0023","unstructured":"Pharmaceuticals and Medical Devices Agency [Internet]. Guideline for clinical evaluation of antibacterial drugs (October 23, 2017, PSEHB\/PED Notification No. 1023-3). Provisional Translation (as of 2020 March) [cited 2022 Aug 29]; [88 p.]. Available from: https:\/\/www.pmda.go.jp\/files\/000234350.pdf"},{"key":"cit0024","unstructured":"Pharmaceuticals and Medical Devices Agency [Internet]. [Reference information regarding guideline for clinical evaluation of antibacterial drugs (October 23, 2017, Administrative Notice)]. [cited 2022 Aug 29]; [5 p]. Japanese. Available from: https:\/\/www.pmda.go.jp\/files\/000221066.pdf"},{"key":"cit0025","unstructured":"Ministry of Health, Labour and Welfare of Japan. [Guidelines for PK\/PD evaluation of antibacterial agents (December 25, 2015, ELD\/PSEB Notification No. 1225-10)]. Jpn J Chemother. 2016;64(2):139\u2013151. Japanese"},{"key":"cit0026","unstructured":"Pharmaceuticals and Medical Devices Agency [Internet]. Report on clinical evaluation of antimicrobial agents for AMR, October 4, 2019 (provisional translation). [cited 2022 Aug 29]; [23 p.]. Available from: https:\/\/www.pmda.go.jp\/files\/000233507.pdf"},{"key":"cit0027","unstructured":"Pharmaceuticals and Medical Devices Agency [Internet]. Tripartite meeting held between EMA, FDA and PMDA towards enhancing development for antibacterial agents. [cited 2022 Aug 29]; [about 2 screens]. Available from: https:\/\/www.pmda.go.jp\/english\/int-activities\/outline\/0018.html"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00270"},{"key":"cit0029","unstructured":"Pharmaceuticals and Medical Devices Agency [Internet]. [Results of re-evaluation of prescription drugs, fiscal year 2004, part 3 (September 30, 2004, PFSB Notification No. 0930002)]. [cited 2022 Aug 29]. Japanese. Available from: https:\/\/www.pmda.go.jp\/files\/000148071.pdf"},{"key":"cit0030","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [Internet]. Efficacy Guidelines. [cited 2022 Aug 29]; [about 2 screens]. Available from: https:\/\/www.ich.org\/page\/efficacy-guidelines"},{"key":"cit0031","unstructured":"Pharmaceuticals and Medical Devices Agency [Internet]. Basic principles on global clinical trials (September 28, 2007, Notification No. 0928010) [cited 2022 Aug 29]; [11 p.]. Available from: https:\/\/www.pmda.go.jp\/files\/000157900.pdf"},{"key":"cit0032","unstructured":"Pharmaceuticals and Medical Devices Agency [Internet]. Basic principles on global clinical trials (reference cases. (Administrative Notice. 2012 Sept 5. cited 2022 Sept 5.12:]. (Administrative Notice. https:\/\/www.pmda.go.jp\/files\/000152969.pdf"},{"key":"cit0033","unstructured":"Pharmaceuticals and Medical Devices Agency [Internet]. Basic principles on global clinical trials (reference cases) (Administrative Notice, September 5, 2012). [cited 2022 Aug 29]; [12 p.]. Available at: https:\/\/www.pmda.go.jp\/files\/000152969.pdf"},{"issue":"4","key":"cit0034","first-page":"253","volume":"35","author":"Ushijima S","year":"2021","journal-title":"Pharmaceut Med"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.35772\/ghm.2019.01017"},{"key":"cit0036","unstructured":"World Health Organization. [Internet]. Japan: national action plan on antimicrobial resistance (AMR) 2016-2020; 2016 April. World Health Organization; 2022. [cited 2022 Aug 29]; [about 2 screens]. Available from: https:\/\/www.who.int\/publications\/m\/item\/japan-national-action-plan-on-antimicrobial-resistance-(amr)"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10111293"},{"key":"cit0038","unstructured":"Japan Agency for Medical Research and Development [Internet]. About AMED. [cited 2022 Aug 29]; [about 2 screens]. Available from: https:\/\/www.amed.go.jp\/en\/aboutus\/index.html"},{"key":"cit0039","unstructured":"Japan Agency for Medical Research and Development [Internet]. Japanese Initiative for Progress of Research on Infectious Disease for global Epidemic (J-PRIDE); 2019 Jul 12 [cited 2022 Aug 29]; [about 3 screens]. Available from: https:\/\/www.amed.go.jp\/en\/program\/list\/01\/06\/005.html"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0414-5"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194679"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-5185-9"},{"key":"cit0043","unstructured":"Japan Agency for Medical Research and Development [Internet]. CiCLE: cyclic innovation for clinical empowerment; 2018. [cited 2022 Aug 29]; [about 3 screens]. Available from: https:\/\/www.amed.go.jp\/en\/program\/list\/17\/01\/001.html"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107427"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202012374"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14899"},{"key":"cit0047","unstructured":"Japan Agency for Medical Research and Development [Internet]. Research Program on Emerging and Re-emerging Infectious Diseases; 2020 Oct 20 [cited 2022 Aug 29]; [about 3 screens]. Available from: https:\/\/www.amed.go.jp\/en\/program\/list\/11\/02\/002.html"},{"key":"cit0048","unstructured":"Japan Agency for Medical Research and Development [Internet]. AMED support for R&D on the novel coronavirus disease (COVID-19) (summary); 2020 Nov 20 [cited 2022 Aug 29]; [about 10 screens]. Available from: https:\/\/www.amed.go.jp\/en\/news\/topics\/covid-19.html"},{"key":"cit0049","unstructured":"Japan Agency for Medical Research and Development [Internet]. Joint Programming Initiative on Antimicrobial Resistance (JPIAMR); 2017 Apr 7 [cited 2022 Aug 29; [about 3 screens]. Available from: https:\/\/www.amed.go.jp\/en\/aboutus\/collaboration\/jpiamr.html"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14807"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12898"},{"key":"cit0052","unstructured":"e-Gov Japanese law portal [Internet]. [Act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices]. Act No. 145 of 1960, Amendment of Act No. 63 of 2019. [cited 2022 Aug 29]; [about 120 screens]. Japanese. Available from: https:\/\/elaws.e-gov.go.jp\/document?lawid=335AC0000000145"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2310"},{"key":"cit0054","unstructured":"Prime Minister\u2019s Office of Japan [Internet]. Health\/medical strategy promotion expert committee (30th). [cited 2022 Aug 29]; [about 2 screens]. Japanese. Available from: https:\/\/www.kantei.go.jp\/jp\/singi\/kenkouiryou\/tyousakai\/dai30\/gijisidai.html"},{"key":"cit0055","unstructured":"Ministry of Health, Labour and Welfare of Japan [Internet]. Health science council (Pharmaceuticals and medical devices system subcommittee). [cited 2022 Aug 29]; [about 3 screens]. Japanese. Available from: https:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-kousei_430263.html"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2251"},{"issue":"3","key":"cit0057","first-page":"198","volume":"4","author":"Arima Y","year":"2021","journal-title":"Jpn Med Assoc J"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.paid.2021.110692"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare8040426"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.3201\/eid2710.204685"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1038\/s41570-021-00313-1"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0034-3"},{"key":"cit0063","unstructured":"US Food and Drug Administration [Internet]. Guidance document: adaptive designs for clinical trials of drugs and biologics guidance for industry. 2019 December [cited 2022 Aug 29]; [about 2 screens]. about 2 screens: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184"},{"key":"cit0066","unstructured":"ClinicalTrials.gov [Internet]. Adaptive COVID-19 Treatment Trial (ACTT). [cited 2022 Aug 29]; [about 13 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04280705"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8920"},{"key":"cit0069","unstructured":"REMAP-CAP: a randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia [Internet]. REMAP-CAP. [cited 2022 Aug 29]. Available from: https:\/\/www.remapcap.org\/"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17022"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-021-00547-7"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.10.010"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1002\/lrh2.10073"},{"key":"cit0074","unstructured":"AMR Action Fund [Internet]. AMR action fund. c2022. [cited 2022 Aug 29]. Available from 2022 Aug 29. https:\/\/www.amractionfund.com\/"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa464"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2021.10.1.6"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2015.98"},{"key":"cit0078","unstructured":"Innovative Medicines Initiative [Internet]. ND4BB: new drugs for bad bugs. [cited 2022 Aug 29]; [about 7 screens]. Available from: https:\/\/www.imi.europa.eu\/projects-results\/project-factsheets\/nd4bb"},{"key":"cit0079","unstructured":"CARB-X: combating antibiotic-resistant bacteria [Internet]. [cited 2022 Aug 29]. Available from: https:\/\/carb-x.org\/"},{"key":"cit0080","unstructured":"US Department of Health and Human Services [Internet]. Biomedical advanced research and development authority. [cited 2022 Aug 29]; [about 4 screens]. about 4 screens: https:\/\/www.phe.gov\/about\/barda\/Pages\/default.aspx"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8603-9-58"},{"key":"cit0082","unstructured":"Japan Pharmaceutical Manufacturers Association [Internet]; Yuasa A, Yoshida M, Tawaragi Y. Situation and issues of development of antimicrobial drugs in Japan and Europe and United States. [cited 2022 Aug 29]; [11 p.]. Available from: https:\/\/www.jpma.or.jp\/english\/globalhealth\/infectious_diseases\/amr\/eki4g60000004bso-att\/eplg5k000000067k.pdf"},{"key":"cit0083","unstructured":"GOV.UK [Internet]. G7 finance ministers\u2019 statement on actions to support antibiotic development. [cited 2022 Aug 29]; [about 3 screens]. Available from: https:\/\/www.gov.uk\/government\/publications\/g7-finance-ministers-statement-on-actions-to-support-antibiotic-development"},{"key":"cit0084","unstructured":"Japan Pharmaceutical Manufacturers Association [Internet]. Japan Pharmaceutical Manufacturers Association; c2006-2021. Recommendations on Antimicrobial Resistance (AMR) [cited 2022 Aug 29]; [about 2 screensAvailable from]: https:\/\/www.jpma.or.jp\/english\/globalhealth\/infectious_diseases\/amr\/recommendations.html"},{"key":"cit0085","unstructured":"AMR Alliance Japan [Internet]. Our policy recommendations. [cited 2022 Aug 29]; [about 5 screens]. Available from: https:\/\/www.amralliancejapan.org\/en\/goals\/"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20110085"},{"key":"cit0087","unstructured":"Prime Minister of Japan and His Cabinet [Internet]. The prime minister in action: headquarters for healthcare policy. (June 1, 2021). [cited 2022 Aug 29]; [about 2 screens]. Available from: https:\/\/japan.kantei.go.jp\/99_suga\/actions\/202106\/_00001.html"},{"key":"cit0088","unstructured":"Ministry of Health, Labour and Welfare of Japan [Internet]. Study group on ensuring the availability of drugs for infectious disease crisis. [cited 2022 Aug 29]; [about 2 screens]. Japanese. Available from: https:\/\/www.mhlw.go.jp\/stf\/shingi\/other-kenkou_kansennsyokikitaiou.html"},{"key":"cit0089","unstructured":"World Health Organization [Internet]. Preparing for pandemics [cited 2022 Aug 29]; [about 2 screens]. Available from: https:\/\/www.who.int\/westernpacific\/activities\/preparing-for-pandemics"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-020-00834-2"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263095"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-021-00223-w"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2021.10.025"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10111426"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00024-3"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2022.2142118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T11:46:25Z","timestamp":1672746385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2022.2142118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":95,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,2]]}},"alternative-id":["10.1080\/14787210.2022.2142118"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2022.2142118","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}